P
Paul Jordan
Researcher at Hoffmann-La Roche
Publications - 20
Citations - 626
Paul Jordan is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Continuous erythropoietin receptor activator & Pharmacodynamics. The author has an hindex of 10, co-authored 20 publications receiving 555 citations.
Papers
More filters
Journal ArticleDOI
Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease
Iain C. Macdougall,Richard Robson,Sylvie Opatrna,Xavier Liogier,Anne Pannier,Paul Jordan,Frank C. Dougherty,Bruno Reigner +7 more
TL;DR: Continuous Erythropoietin Receptor Activator has a prolonged and comparable half-life after intravenous or subcutaneous injection, suggesting that extended administration intervals may be feasible in patients with CKD.
Journal ArticleDOI
Inhibition of 11β-HSD1 with RO5093151 for non-alcoholic fatty liver disease: a multicentre, randomised, double-blind, placebo-controlled trial
Norbert Stefan,Markus Ramsauer,Paul Jordan,Bettina Nowotny,Konstantinos Kantartzis,Jürgen Machann,Jong-Hee Hwang,Peter Nowotny,Sabine Kahl,Jürgen Harreiter,Silke Hornemann,Arun J. Sanyal,Paul M. Stewart,Andreas Pfeiffer,Alexandra Kautzky-Willer,Michael Roden,Hans-Ulrich Häring,Sabine Fürst-Recktenwald +17 more
TL;DR: Inhibition of 11β- HSD1 by RO5093151 was effective and safe in reducing liver-fat content, suggesting that targeting of 11 β-HSD1 might be a promising approach for the treatment of non-alcoholic fatty liver disease.
Journal ArticleDOI
Vitamin E and vitamin A concentrations in plasma adjusted for cholesterol and triglycerides by multiple regression.
TL;DR: A new multiple regression-based method for adjusting vitamins A and E concentrations for cholesterol and triglycerides with previous methods shows that the new method can reduce influence of the concurrent lipids.
Journal ArticleDOI
A phase 1 healthy male volunteer single escalating dose study of the pharmacokinetics and pharmacodynamics of risdiplam (RG7916, RO7034067), a SMN2 splicing modifier.
Stefan Sturm,Andreas Günther,Birgit Jaber,Paul Jordan,Nada Al Kotbi,Nikhat Parkar,Yumi Cleary,Nicolas Frances,Tobias Bergauer,Katja Heinig,Heidemarie Kletzl,Anne Marquet,Hasane Ratni,Agnès Poirier,Lutz Müller,Christian Czech,Omar Khwaja +16 more
TL;DR: The objectives of this entry‐into‐human study were to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of risdiplam, and the effect of the strong CYP3A inhibitor itraconazole on the PK of ris diplam in healthy male volunteers.
Journal ArticleDOI
A Comparison of the Theoretical Relationship between HDL Size and the Ratio of HDL Cholesterol to Apolipoprotein A-I with Experimental Results from the Women's Health Study
TL;DR: The results offer new insights into HDL structure, composition and remodeling and suggest that the HDL-C/ApoA-I ratio might be a readily available biomarker for estimating HDL size and HDL-P.